These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18719056

  • 1. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
    Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ.
    Chest; 2009 Jan; 135(1):130-136. PubMed ID: 18719056
    [Abstract] [Full Text] [Related]

  • 2. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
    Chin KM, Channick RN, Kim NH, Rubin LJ.
    Chest; 2007 Sep; 132(3):786-92. PubMed ID: 17646224
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.
    Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Kuwana M, Fukuda K, Satoh T.
    PLoS One; 2015 Sep; 10(4):e0121894. PubMed ID: 25844932
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [Abstract] [Full Text] [Related]

  • 9. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, Matsubara H, Ito H.
    Vasc Health Risk Manag; 2015 Sep; 11():265-70. PubMed ID: 25999730
    [Abstract] [Full Text] [Related]

  • 10. Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol.
    Rossi R, Coppi F, Sgura F, Monopoli D, Boriani G.
    Pulm Pharmacol Ther; 2018 Apr; 49():147-151. PubMed ID: 28642014
    [Abstract] [Full Text] [Related]

  • 11. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.
    Am J Cardiol; 2010 May 15; 105(10):1485-9. PubMed ID: 20451700
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E, Sitbon O, Cottin V, Prévot G, Canuet M, Bourdin A, de Groote P, Rottat L, Gressin V, Jaïs X, Humbert M, Simonneau G.
    Int J Cardiol; 2014 Apr 01; 172(3):561-7. PubMed ID: 24529947
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T, Lemarié JC, Simonneau G.
    Am Heart J; 2014 Feb 01; 167(2):210-7. PubMed ID: 24439982
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst R.
    Int J Clin Pract Suppl; 2010 Nov 01; (168):23-32. PubMed ID: 20939843
    [Abstract] [Full Text] [Related]

  • 20. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
    Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, Parent F, Simonneau G.
    Eur Respir J; 1999 Jun 01; 13(6):1351-6. PubMed ID: 10445611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.